Streetbeat News

Earnings

SSKN

Strata Skin Sciences (NASDAQ:SSKN) reported Q4 earnings with an EPS of $-0.04, missing estimates by -100.0% and a revenue decrease of $1.91 million from the previous year. Despite beating EPS estimates last quarter, this marks a significant downturn.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:30 pm

TOI

Oncology Institute (NASDAQ:TOI) reported Q4 earnings with a significant miss on estimated earnings by -91.0%, posting an EPS of $-0.21 against an estimate of $-0.11. Despite this, revenue increased by $14.36 million from the same period last year. In the previous quarter, despite missing EPS estimates, the share price increased by 28% the following day.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:30 pm

AQMS

Aqua Metals reported its FY23 financial results, highlighting a net loss of $23.9 million, or $(0.25) per share, compared to a net loss of $15.4 million, or $(0.20) per share, in 2022. The company, focusing on recycling metals from lithium-ion batteries, saw increased expenses and generated no significant revenue. Adjusted net loss was $19.1 million, or $(0.20) per share. Cash and equivalents stood at $16.5 million by year-end.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:30 pm

TOI

The Oncology Institute (NASDAQ:TOI) reported Q4 2023 earnings with a GAAP EPS of $(0.21), missing the $(0.11) estimate by 90.91%, but sales of $85.788M exceeded the $82.042M estimate by 4.57%, marking a 20.11% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:28 pm

FUL

H.B. Fuller's stock price declined following the announcement of mixed financial results for the first quarter. The company's performance did not fully meet market expectations, leading to a negative reaction from investors.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:26 pm

PLBY

PLBY Group (NASDAQ:PLBY) reported Q4 earnings with an EPS of $-0.05, beating estimates by 64.0% but with a revenue decrease of $29.15 million from the previous year. The company had previously missed EPS estimates last quarter, resulting in a 25.0% share price drop the following day. The report provides a detailed comparison of PLBY's performance over the last four quarters, highlighting fluctuations in EPS and revenue.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:25 pm

PLBY

PLBY Group reported Q4 2023 earnings with a GAAP EPS of $(0.05), surpassing the $(0.14) estimate. Sales reached $39.364M, exceeding the $32.275M forecast but marking a 12.31% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:24 pm

CXM

Sprinklr (NYSE:CXM) reported Q4 earnings of $0.12 per share, surpassing the $0.09 estimate, a 100% increase from last year. Sales reached $194.21M, beating the $188.73M estimate, marking a 17.47% increase from the previous year.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 8:23 pm

RH

RH shares are trading higher following the announcement of their Q4 financial results and the issuance of future guidance.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:21 pm

MREO

Mereo BioPharma Group (NASDAQ:MREO) reported a narrower quarterly loss of $(0.04) per share, improving from $(0.07) per share year-over-year, with sales reaching $10.00 million.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 8:21 pm